Charles Schwab Investment Management Inc. Sells 303,087 Shares of Insmed, Inc. $INSM

Charles Schwab Investment Management Inc. cut its holdings in shares of Insmed, Inc. (NASDAQ:INSM) by 18.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,299,568 shares of the biopharmaceutical company’s stock after selling 303,087 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.61% of Insmed worth $130,789,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. ORG Partners LLC raised its position in shares of Insmed by 220.2% in the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 196 shares during the period. Hilltop National Bank bought a new stake in Insmed during the 2nd quarter valued at $28,000. FNY Investment Advisers LLC bought a new stake in Insmed during the 2nd quarter valued at $33,000. LRI Investments LLC purchased a new stake in shares of Insmed during the second quarter worth $59,000. Finally, Strategic Investment Solutions Inc. IL bought a new position in shares of Insmed in the first quarter worth $79,000.

Insmed Trading Down 2.2%

INSM stock opened at $204.51 on Friday. The company has a market capitalization of $43.62 billion, a PE ratio of -35.82 and a beta of 1.05. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68. Insmed, Inc. has a one year low of $60.40 and a one year high of $209.77. The company’s 50 day moving average price is $172.67 and its two-hundred day moving average price is $128.67.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.40). The business had revenue of $142.34 million for the quarter, compared to the consensus estimate of $114.33 million. Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. Insmed’s revenue for the quarter was up 52.4% on a year-over-year basis. During the same period in the prior year, the business posted ($1.27) EPS. Insmed has set its FY 2025 guidance at EPS. As a group, analysts predict that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Insider Activity

In other Insmed news, insider Michael Alexander Smith sold 27,130 shares of Insmed stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $183.78, for a total value of $4,985,951.40. Following the transaction, the insider directly owned 54,902 shares of the company’s stock, valued at $10,089,889.56. The trade was a 33.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Melvin Md Sharoky sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $145.39, for a total value of $1,453,900.00. Following the completion of the sale, the director owned 262,675 shares of the company’s stock, valued at $38,190,318.25. The trade was a 3.67% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 257,922 shares of company stock valued at $44,556,283. Company insiders own 3.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Stifel Nicolaus boosted their price objective on Insmed from $121.00 to $145.00 and gave the company a “buy” rating in a research note on Thursday, August 14th. Morgan Stanley upped their price target on Insmed from $126.00 to $144.00 and gave the company an “equal weight” rating in a research report on Thursday, August 21st. Wells Fargo & Company raised their price objective on shares of Insmed from $171.00 to $217.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. Bank of America boosted their price objective on shares of Insmed from $142.00 to $187.00 and gave the company a “buy” rating in a research note on Monday, October 27th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Insmed in a research note on Wednesday, October 8th. Nineteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Insmed has a consensus rating of “Moderate Buy” and a consensus target price of $175.53.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.